Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: In an open-label extension (OLE) of a 16-week, randomized, double blind (DB), placebo (PBO)-controlled, phase 3 study (GO-AHEAD; NCT1453725) in patients with nonradiographic axial spondyloarthritis (nr-axSpA)1, we assessed quality of life (QoL) in patients with objective signs of inflammation at baseline.
Methods: Patients received GLM 50mg Q4W during the 44-week OLE (36-week efficacy period; 8-week safety follow-up). QoL evaluations were specified in patients with objective inflammation (MRI sacroiliitis+ and/or C-reactive protein >upper limit of normal) and included Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL), 36-item Short Form Health Survey (SF‑36), and EuroQol Group 5 Dimensions Health Questionnaire (EQ-5D) Index and Health State (0–10cm VAS), and Work Productivity and Activity Impairment (WPAI) at weeks 16 and 52 and the Patient’s Global Disease Assessment (PGDA; 0–10cm VAS) at weeks 16, 20, 24, 32, 40, and 52.
Results: There were 153 patients with objective inflammation at baseline (of the DB period: GLM=76; PBO=77) who were then treated in the OLE. At week 52, patients continuing GLM and those switched from PBO to GLM in the OLE demonstrated improvement in QoL parameters (Figure) Mean (SD) change from baseline in Overall Work Impairment scores were -21.2 (24.7) (GLM) and -8.4 (28.5) (PBO) at week 16; at week 52, mean (SD) changes were -31.1 (GLM/GLM) and -26.5 (27.2) (PBO/GLM).
Conclusion: Among patients with objective inflammation before treatment in the DB phase, those who continued GLM in the OLE had continued benefits in QoL and work productivity, and those who switched to GLM in the OLE from PBO in the DB phase had notable improvement in QoL and work productivity. Reference: 1. Sieper J, et al. Arthritis Rheum. 2015;67(10):2702-2712.
To cite this abstract in AMA style:Maksymowych W, Dougados M, Sieper J, Braun J, Bergman G, Curtis SP, Tzontcheva A, Philip G, Huyck S, van der Heijde D. Patient-Reported Quality of Life in Patients with Baseline Objective Signs of Inflammation and Active Nonradiographic Axial Spondyloarthritis Treated with Golimumab: Results of the Open-Label Extension of a Randomized, Double-Blind Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/patient-reported-quality-of-life-in-patients-with-baseline-objective-signs-of-inflammation-and-active-nonradiographic-axial-spondyloarthritis-treated-with-golimumab-results-of-the-open-label-extensio/. Accessed November 30, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-quality-of-life-in-patients-with-baseline-objective-signs-of-inflammation-and-active-nonradiographic-axial-spondyloarthritis-treated-with-golimumab-results-of-the-open-label-extensio/